Introduction:
The purpose of this study was to determine the diagnostically significant laboratory parameters which are predictors of sensorineural hearing loss in the blood of children receiving gentamicin, and to develop ways of its correction.

Material and methods:
The study included 50 children who were hospitalized at the Republican Perinatal Center of the Tashkent Pediatric Medical Institute in need of antibiotic treatment. They had not recently received aminoglycoside antibiotics but anamnesis showed that these children had experienced their prolonged use. The patients were divided into 2 groups, as follows. Group 1 comprised children who were prescribed gentamicin as a course of treatment at an age-appropriate dose of 2–5 mg/kg, 2 times a day (n = 25). The second group consisted of 25 patients who were prescribed gentamicin with simultaneous administration of phosphogliv. A control group (n = 20) consisted of children who did not receive gentamicin.

Results:
Gentamycin-induced intoxication was determined by diagnostically significant laboratory criteria for neuron-sensitive deafness. It was found that phosphogliv, which contains essential phospholipids in complex with aminoglycosides, could prevent neuron-sensitive deafness in children. Accompanying the use of gentamicin and phosphogliv in the second group, there was a significant decrease in the average level of molecular peptides in the blood, and the concentration of malondialdehyde decreased 2.4 times relative to the first group (p < 0.05).

Conclusions:
Use of gentamicin with simultaneous essential phospholipids helps to reduce the amount of malondialdehyde in the blood, reduce medium-molecular peptides, and increase the activity of enzyme-protecting superoxide dismutase.